|
Post by tunis on Apr 23, 2015 20:23:35 GMT
NEWARK, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The shares and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). StemCells intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and research and development. Maxim Group LLC is acting as sole book-running manager for the offering. The securities will be offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective registration statement, a copy of which may be obtained, when available, at the website of the SEC at www.sec.gov. Electronic copies of the preliminary prospectus also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at 212-895-3500. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About StemCells, Inc. StemCells, Inc. is currently engaged clinical development of its platform technology, HuCNS-SC(R) (purified human neural stem cells) as a potential treatment for disorders of the central nervous system (CNS). Interim data from the Company's Phase I/II clinical trial in thoracic spinal cord injury (SCI) shows measurable gains involving multiple sensory modalities and segments, including the conversion of 2 of 7 patients enrolled in the study with complete injuries (AIS A) converting to incomplete injuries (AIS B), post-transplant. Enrollment has recently commenced in the Company's Phase II clinical trial in cervical SCI. StemCells, Inc. has also completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration (GA-AMD), the most severe form of dry AMD, which is the leading cause of blindness in the elderly. Based upon interim results for subjects with twelve months data, the Company reported a 70 percent reduction in the rate of disease progression as compared to the control (untreated) eye and a 65 percent reduction in the rate of disease progression as compared to the expected natural history of the disease. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cell
|
|
|
Post by RLC on Apr 23, 2015 20:35:23 GMT
NEWARK, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The shares and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). StemCells intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and research and development. Maxim Group LLC is acting as sole book-running manager for the offering. The securities will be offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective registration statement, a copy of which may be obtained, when available, at the website of the SEC at www.sec.gov. Electronic copies of the preliminary prospectus also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at 212-895-3500. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About StemCells, Inc. StemCells, Inc. is currently engaged clinical development of its platform technology, HuCNS-SC(R) (purified human neural stem cells) as a potential treatment for disorders of the central nervous system (CNS). Interim data from the Company's Phase I/II clinical trial in thoracic spinal cord injury (SCI) shows measurable gains involving multiple sensory modalities and segments, including the conversion of 2 of 7 patients enrolled in the study with complete injuries (AIS A) converting to incomplete injuries (AIS B), post-transplant. Enrollment has recently commenced in the Company's Phase II clinical trial in cervical SCI. StemCells, Inc. has also completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration (GA-AMD), the most severe form of dry AMD, which is the leading cause of blindness in the elderly. Based upon interim results for subjects with twelve months data, the Company reported a 70 percent reduction in the rate of disease progression as compared to the control (untreated) eye and a 65 percent reduction in the rate of disease progression as compared to the expected natural history of the disease. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cell I think I'm going to have to initiate a small position here after this one. STEM is around ~$50 million MC and has data expected out later this year. Seems like a great trading opportunity IMO.
|
|
|
Post by CM kipper007 on Apr 23, 2015 22:22:18 GMT
NEWARK, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The shares and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). StemCells intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and research and development. Maxim Group LLC is acting as sole book-running manager for the offering. The securities will be offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective registration statement, a copy of which may be obtained, when available, at the website of the SEC at www.sec.gov. Electronic copies of the preliminary prospectus also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at 212-895-3500. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About StemCells, Inc. StemCells, Inc. is currently engaged clinical development of its platform technology, HuCNS-SC(R) (purified human neural stem cells) as a potential treatment for disorders of the central nervous system (CNS). Interim data from the Company's Phase I/II clinical trial in thoracic spinal cord injury (SCI) shows measurable gains involving multiple sensory modalities and segments, including the conversion of 2 of 7 patients enrolled in the study with complete injuries (AIS A) converting to incomplete injuries (AIS B), post-transplant. Enrollment has recently commenced in the Company's Phase II clinical trial in cervical SCI. StemCells, Inc. has also completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration (GA-AMD), the most severe form of dry AMD, which is the leading cause of blindness in the elderly. Based upon interim results for subjects with twelve months data, the Company reported a 70 percent reduction in the rate of disease progression as compared to the control (untreated) eye and a 65 percent reduction in the rate of disease progression as compared to the expected natural history of the disease. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cell I think I'm going to have to initiate a small position here after this one. STEM is around ~$50 million MC and has data expected out later this year. Seems like a great trading opportunity IMO. How would you go about trading this one? I'm just not sure when the low point is going to be. Depending on lock in for the new shares, then the new investors could flood the market and just hold the warrants.
|
|
|
Post by RLC on Apr 23, 2015 22:39:38 GMT
I think I'm going to have to initiate a small position here after this one. STEM is around ~$50 million MC and has data expected out later this year. Seems like a great trading opportunity IMO. How would you go about trading this one? I'm just not sure when the low point is going to be. Depending on lock in for the new shares, then the new investors could flood the market and just hold the warrants. The offering is bound to make things a bit volatile in the near term. Volatility usually creates trading opportunities. Couple that with the company being near a 3-year low and with a catalyst (data release from 1st cohort of spinal cord injury trial) later this year. I'm sure it could drift lower from here, and until the offering is priced I wouldn't feel comfortable taking a large position. However, after the company funds itself for the near term, the downside risk will be somewhat mitigated IMO.
|
|
|
Post by CM kipper007 on Apr 23, 2015 22:47:56 GMT
How would you go about trading this one? I'm just not sure when the low point is going to be. Depending on lock in for the new shares, then the new investors could flood the market and just hold the warrants. The offering is bound to make things a bit volatile in the near term. Volatility usually creates trading opportunities. Couple that with the company being near a 3-year low and with a catalyst (data release from 1st cohort of spinal cord injury trial) later this year. I'm sure it could drift lower from here, and until the offering is priced I wouldn't feel comfortable taking a large position. However, after the company funds itself for the near term, the downside risk will be somewhat mitigated IMO. FYI, I think the results from the spinal trail are next month in Montreal, then the results from the eye trials are the following month in Stockholm. Slides 11 and 25 wsw.com/webcast/needham71/stem/
|
|
|
Post by RLC on Apr 23, 2015 23:45:17 GMT
The offering is bound to make things a bit volatile in the near term. Volatility usually creates trading opportunities. Couple that with the company being near a 3-year low and with a catalyst (data release from 1st cohort of spinal cord injury trial) later this year. I'm sure it could drift lower from here, and until the offering is priced I wouldn't feel comfortable taking a large position. However, after the company funds itself for the near term, the downside risk will be somewhat mitigated IMO. FYI, I think the results from the spinal trail are next month in Montreal, then the results from the eye trials are the following month in Stockholm. Slides 11 and 25 wsw.com/webcast/needham71/stem/Thanks for the info kipp. I'm assuming you don't see STEM as worthy trade?
|
|
|
Post by Whidbeygal CM 20/20 on Apr 23, 2015 23:48:32 GMT
STEM is below a dollar. NASDAQ requirements are also in jeopardy.
|
|
|
Post by JHam on Apr 24, 2015 0:18:46 GMT
Wow! Well this is good news for anyone who was looking to get into this. It will probably sink much harder tomorrow than the current $.72 (-12%) AH price, but once this raise is out of the way I may look to open a position. Dilution out of the way with catalysts on the horizon.
|
|
|
Post by tunis on Apr 24, 2015 0:36:19 GMT
Company does a lot of things good but none of them great.
|
|
|
Post by CM kipper007 on Apr 24, 2015 0:43:24 GMT
FYI, I think the results from the spinal trail are next month in Montreal, then the results from the eye trials are the following month in Stockholm. Slides 11 and 25 wsw.com/webcast/needham71/stem/Thanks for the info kipp. I'm assuming you don't see STEM as worthy trade? I am just not experienced enough to make that call and these are just my thoughts. They went through a bit of a ringer recently, selling off some assets, losing the funding, their CEO (?) selling into a rally and shifting when results will be out. I don't have a lot of hope for their eye program. Not that I have done extensive research, but I have not heard about any great results that can compete with OCAT's. If they have weak results in June, I just see that trial as being a money eater for the company. They mentioned that there was some visual improvement, but it was only noticing changes in contrast if memory serves. Although they may have halted further degeneration So that really leaves me thinking their spinal program is going to be their bread and butter. I really do hope this is a successful trial as it will be a life changer for people. But going off the above (if I am right!!), the only way their price will pop is if the market thinks that phase 2 for the spinal program will lead to success down the road. With the raise so close to their results being released, this could be a big drain on PPS if the market isn't impressed. And with the recent negative news mentioned above, I am not sure I would place a bet on this. Following that entry point with the offering looming, close to the results being released is something I am going to follow for future reference. Very interested to hear what the rest of the group think though.
|
|
|
Post by Whidbeygal CM 20/20 on Apr 24, 2015 1:04:14 GMT
Look at the chart. I previously owned STEM, got out when the scientist questioned the quality of the cells. There is a difference in a trader/gambler.
I personally would not touch it .
My opinion.
|
|
|
Post by selluwud on Apr 24, 2015 12:05:59 GMT
Hasn't STEM been on the brink of delisting before and had to do a reverse split to keep the pps above the minimum. Here they go again, just watch.
|
|
|
Post by dayanand33 on Apr 24, 2015 14:36:45 GMT
Who in the right mind would buy at $.70 when it is available in market for $0.54 Is it possible that this offering goes under subscribed? If so then the last resort is going the lincoln park route, just like OCATA did.
|
|
|
Post by jckrdu on Apr 24, 2015 14:54:28 GMT
Who in the right mind would buy at $.70 when it is available in market for $0.54 Is it possible that this offering goes under subscribed? If so then the last resort is going the lincoln park route, just like OCATA did. Someone may want to check my math, but is this offering 50% dilution?
Current shares issued is about 70 million
They're looking to raise $25 million selling shares at .70 which would equate to issuing 35 million more shares
|
|
|
Post by dayanand33 on Apr 24, 2015 15:40:33 GMT
Who in the right mind would buy at $.70 when it is available in market for $0.54 Is it possible that this offering goes under subscribed? If so then the last resort is going the lincoln park route, just like OCATA did. Someone may want to check my math, but is this offering 50% dilution?
Current shares issued is about 70 million
They're looking to raise $25 million selling shares at .70 which would equate to issuing 35 million more shares
Yep, I agree that it is about 50% of the current outstanding standing shares (~70 million outstanding) That's helluva dilution before results. How do I read this? Aren't they confident in their results that are due in June? I was hoping that they would raise cash by showing off their results.
|
|
|
Post by CM kipper007 on Apr 24, 2015 16:40:17 GMT
I wouldn't be shocked if they go back to CIRM to try and get funding there.
They would need to give a large percentage of future profits, but would keep the lights on.
|
|
|
Post by JHam on Apr 27, 2015 8:00:25 GMT
Who in the right mind would buy at $.70 when it is available in market for $0.54 Is it possible that this offering goes under subscribed? If so then the last resort is going the lincoln park route, just like OCATA did. dayand, It could. Current shareholders are definitely going to get (already getting) crushed. Could be an interesting play once the dust settles and the full extent of the damage is known. For those of you suggesting to buy OCAT over here in the STEM forum, why do you think things will be any different for OCAT when they do their next offering? The market did not care too much for OCAT a few months ago and in my opinion this is exactly the kind of dilution OCAT was headed for. Thankfully for current shareholders, Wotton pulled the plug, or I imagine the result would have been similar to what we are seeing with STEM. OCAT will still have to do a raise at some point. Hopefully they will have something to make them more appealing than the last time.
|
|
|
Post by dayanand33 on Apr 27, 2015 12:16:33 GMT
Who in the right mind would buy at $.70 when it is available in market for $0.54 Is it possible that this offering goes under subscribed? If so then the last resort is going the lincoln park route, just like OCATA did. dayand, It could. Current shareholders are definitely going to get (already getting) crushed. Could be an interesting play once the dust settles and the full extent of the damage is known. For those of you suggesting to buy OCAT over here in the STEM forum, why do you think things will be any different for OCAT when they do their next offering? The market did not care too much for OCAT a few months ago and in my opinion this is exactly the kind of dilution OCAT was headed for. Thankfully for current shareholders, Wotton pulled the plug, or I imagine the result would have been similar to what we are seeing with STEM. OCAT will still have to do a raise at some point. Hopefully they will have something to make them more appealing than the last time. If the offering is made after the results are out, it is likely to find buyers at a good price, assuming the results are good.
|
|
|
Post by JHam on Apr 27, 2015 12:50:27 GMT
I went ahead and moved some posts from this forum as well to the *Mish-Mash* thread as they had very little to do with STEM and were more or less solicitations of other stocks.
JHam
|
|
|
Post by jckrdu on Apr 27, 2015 15:06:01 GMT
Started a position here at .60 this morning. Still lots of unknowns with this capital raise... we'll see.
|
|